SLC5A2 and fatty liver disease: Compared with monotherapy, the combination of exenatide, a GLP-1 receptor agonist, and dapagliflozin, an SGLT-2 inhibitor, showed superior efficacy in ameliorating markers of hepatic steatosis and fibrosis in patients with T2DM [19].